TY - JOUR
T1 - Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma
AU - Omri, Loubna
AU - Naigeon, Marie
AU - Flippot, Ronan
AU - Gavira-Díaz, Javier
AU - Poveda-Ferriols, Jesus
AU - Nguyen, Dan
AU - Abdi, Chaimae
AU - Arroyo-Salgado, Alvaro
AU - Chaput, Nathalie
AU - Velasco, Guillermo de
AU - Albigès, Laurence
AU - Carril-Ajuria, Lucía
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/1/1
Y1 - 2024/1/1
N2 - Immune checkpoint inhibitors (ICI)-based combinations have become the standard first-line treatment for advanced clear cell renal cell carcinoma (ccRCC). Despite significant improvements in survival and the achievement of sustained long-term responses, a subset of patients remains refractory to ICI, and most will eventually develop resistance. Thus, identifying predictive biomarkers for ICI efficacy and resistance is essential for optimizing therapeutic strategies. Up to now, tissue-based biomarkers have not been successful as predictive biomarkers in RCC. Circulating blood-based biomarkers offer a promising alternative. These biomarkers, including circulating immune cells, soluble factors, tumor-derived markers, and those based on metabolomics, are less invasive, offer reproducibility over time, and provide a comprehensive assessment of tumor biology and patient immune status, as well as allow dynamic monitoring during treatment. This review aims to evaluate the current evidence on the different candidate circulating biomarkers being investigated for their potential to predict ICI efficacy in RCC patients.
AB - Immune checkpoint inhibitors (ICI)-based combinations have become the standard first-line treatment for advanced clear cell renal cell carcinoma (ccRCC). Despite significant improvements in survival and the achievement of sustained long-term responses, a subset of patients remains refractory to ICI, and most will eventually develop resistance. Thus, identifying predictive biomarkers for ICI efficacy and resistance is essential for optimizing therapeutic strategies. Up to now, tissue-based biomarkers have not been successful as predictive biomarkers in RCC. Circulating blood-based biomarkers offer a promising alternative. These biomarkers, including circulating immune cells, soluble factors, tumor-derived markers, and those based on metabolomics, are less invasive, offer reproducibility over time, and provide a comprehensive assessment of tumor biology and patient immune status, as well as allow dynamic monitoring during treatment. This review aims to evaluate the current evidence on the different candidate circulating biomarkers being investigated for their potential to predict ICI efficacy in RCC patients.
KW - Renal cell carcinoma
KW - circulating biomarkers
KW - immune-checkpoint inhibitors
KW - liquid biopsy
UR - http://www.scopus.com/inward/record.url?scp=85205138141&partnerID=8YFLogxK
U2 - 10.37349/etat.2024.00271
DO - 10.37349/etat.2024.00271
M3 - Review article
AN - SCOPUS:85205138141
SN - 2692-3114
VL - 5
SP - 1199
EP - 1222
JO - Exploration of Targeted Anti-tumor Therapy
JF - Exploration of Targeted Anti-tumor Therapy
ER -